| GUEST EDITORIAL
International Journal of Aesthetic and Anti-Ageing Medicine Informa Healthcare, 119 Farringdon Road, London, EC1R 3DA, UK
www.informahealthcare.com
Managing Editor Rosalind Hill
rosalind.hill@informa.com
Publisher Simon Percival +44(0)20 7017 4060
simon.percival@
informa.com
Head of Marketing Alan Abery
alan.abery@informa.com
Marketing Executive Susie Comben
susie.comben@
informa.com
Production Director Stewart Gardiner +44 (0)20 7017 6775
stewart.gardiner@
informa.com
Managing Director Nick Del Rio
nick.delrio@
informausa.com
Web Designer/Producer Marcus Hurley +44 (0)20 7017 4252
marcus.hurley@
informa.com
Art Director David ‘Spike’ McCormack
spike@spikedesigns.co.uk
Production & Ads Department
primeadverts@informa.com
Please send your manuscripts and press releases to:
rosalind.hill@informa.com
■ All manuscripts submitted to the journal are first evaluated on the basis of scientific quality, originality, appropriateness, contribution to the field and style. Suitable manuscripts are then subject to rigorous peer review.
■ Formal submissions for peer reviewed papers/ Articles. Manuscripts and accompanying files should be prepared in accordance with our Author Guidelines, which are available via
www.prime-journal.com)
All content © 2012 Informa UK Ltd Images ©
Shutterstock.com, unless otherwise stated
S
ince the start of 2012, the medical aesthetics industry has been under intense media scrutiny as a result of the PIP breast implant scandal ® an event which has raised key questions about the way our industry currently operates, and also how it needs to evolve moving forwards. IÕm sure I speak for all those in the industry when I say that this was a terrible scandal and our sympathy goes out to the women who have had PIP implants. However, this
issue does raise the point that quality and heritage are very important features that both consumers and healthcare practitioners should always look for in a medical aesthetic product. Quality should stand for strict manufacturing processes; proper conformance to standards; robust evidence to support a product and excellent health professional training. By heritage, we mean that products are supported by substantial clinical evidence, gathered over time and developed by manufacturers who have commitment and dedication. ItÕs odd to consider that people were driven to choose PIP implants based on price when in fact,
cheapness does not have a place in medical aesthetics. Cutting corners on a medical aesthetic product or treatment simply does not make sense ® in fact, our estimates show that the cost of the implant in a typical breast augmentation procedure is around 14%, with product cost of about 35% in a typical dermal filler treatment, and 27% for the product in a toxin treatment. Sadly, the effect of the PIP cost-cutting strategy has not only left thousands of patients in emotional distress, but has placed a genuine risk to the reputation of the medical aesthetics industry and to the aesthetics community as a whole. So how do we ensure the health of our industry moving forwards? We all have a role to play in
order to ensure continued outstanding outcomes for patients and preservation of the long-term health and reputation of medical aesthetics. Manufacturers must focus on making the highest quality products, regardless of costs, demonstrate a commitment to safety and outcomes, and show a genuine commitment to training physicians on the use of their products. Physicians are responsible for developing good product-specific knowledge and skills, and being experts in selecting the products for their patients that have the right heritage and quality to ensure great outcomes. And finally, patients also have a responsibility to do their homework; explore their physicianÕs product-specific skills and to ask about the quality and heritage of the products being recommended to them. Regulators have the responsibility to assess the registration information on all medical products and to only grant approval to products that have proven safety and benefit. There will doubtless be many more changes and developments in
our industry as a result of this issue. However, by continuing to keep our focus firmly on quality and heritage, we can help restore consumer confidence in the medical aesthetics industry.
Douglas Ingram President, Allergan EAME
PRIME JOURNAL EDITORIAL BOARD BOARD MEMBER SPECIALISM
Dr Claude Dalle
Dr Wilmar Accursio Dr Pierre Andre Dr Ashraf Badawi
Anti-ageing & aesth. medicine France Endocrinologist Dermatology Dermatology
France Egypt
Dr Janethy Balakrishnan Dermatology Dr Lakhdar Belhaouari Dr Philippe Berros Dr Dario Bertossi
Plastic surgery
Oculoplastic surgery Maxillofacial surgery
Dr Jean Christophe Bichet Plastic surgery Dr Philippe Blanchemaison Phlebology Dr Pierre Bouhanna Dr Fahd Benslimane Prof Wayne Carey
Dr Claude Chauchard Dr Olivier Claude
Dr Christophe de Jaeger Geriatrics Prof Ilaria Ghersetich Dr Monika Golkova Dr Raul Gonzalez Prof Eckart Haneke Dr Steven Hopping Prof Xiaoyan Jiang
Dermatology Neurologist
Plastic surgery Dermatology Plastic surgery Genetics
Prof Andreas Katsambas Dermatology
Dermatology – Hair surgery Plastic Surgeon Dermatology
Anti-ageing medicine Plastic surgery
Malaysia France
Monaco Italy
France France France
Morocco Canada France France France Italy
Czech Republic Brazil
Germany USA
Canada Greece
COUNTRY Brazil
BOARD MEMBER SPECIALISM Dr Mario Krause
Dr David Lai
Dr Marina Landau Dr Jean-Luc Levy Dr Sohail Mansoor Prof Leonardo Marini Dr Georges Mouton Dr Ruben Muhlberger Prof Daniel Pella Dr Vincenzo Penna
Prof Ascanio Polimeni Dr Herve Raspaldo Dr Constantin Stan Dr Pakpilai Thavisin Dr Mario Trelles Dr Ines Verner Dr Octavio Viera
Prof Bernard Weber Prof Alfred Wolf Christophe Luino Catherine Decuyper Wendy Lewis
Anti-ageing medicine Anti-ageing medicine Dermatology Dermatology Dermatology Dermatology
Sports medicine
Anti-ageing medicine Cardiology
Dr Chariya Petchngaovilai Dermatology Dr Eric Plot
Plastic surgery Plastic surgery
Neuro-endocrinology Facial plastic surgery Plastic surgery
COUNTRY Germany
Hong Kong Israel
France UK
Italy Belgium
Argentina Slovakia Germany Thailand France Italy
France
Dermatology & Anti-ageing medicine Thailand Plastic surgery Dermatology
Israel
Anti-ageing medicine; pediatry Spain Genetician
Gynaecology USA
Luxembourg Germany
Industry expert & consultant France Industry expert & consultant France Industry expert
prime-journal.com | January/February 2012 ❚ 5
Romania Spain
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112